Reading this on a mobile device? Try our optimized mobile version here:

January 23, 2013
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
  • Most neurologists willing to use Amyvid if reimbursed, survey says
    Most U.S. neurologists are willing to use the PET imaging agent Amyvid to assess patients for Alzheimer's disease if the scan will be covered by health insurance, according to findings from a study published in the Journal of Alzheimer's Disease. Most of the respondents planning to use the agent said they would do so as part of an adjunctive diagnostic test to rule out or confirm the disease, the survey found. Ninety-two percent of respondents said that before patients undergo the test, they should be informed of how the results will be interpreted. The findings indicate experts in the field see a clinical value in using the test, researchers said. (1/22) LinkedInFacebookTwitterEmail this Story
  Clinical News & Research 
  • Study: PET could diagnose CTE in patients
    Results from PET imaging with the FDDNP tracer showed tau protein accumulation in the brains of five retired National Football League players with suspected chronic traumatic encephalopathy, according to a study in The American Journal of Geriatric Psychiatry. The findings were consistent with results from autopsies of players who had the condition, researchers said. They added that the study, while small, may pave the way toward the routine use of PET scans to prevent the development of the disease and to manage patients with the condition. The New York Times (tiered subscription model) (1/22) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  News from the Field 
  • Opinion: Pharma must sort out best reimbursement channels
    On a case-by-case basis, the pharmaceutical industry must evaluate the most favorable reimbursement channels to optimize return on investment, Ben Comer writes. "Identification of lower-cost sites of care under the medical benefit is often the most significant area of opportunity [for savings] in terms of total dollars," the Artemetrx report "Specialty Drug Trend Across the Pharmacy and Medical Benefit" says. Private and public plans will seek cost savings when possible as biologic drug approvals and specialty drug costs increase. (1/21) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • Institutes collaborate on translational research
    The Scripps Research Institute, the Centre for Drug Research and Development in Canada, the Lead Discovery Center in Germany, the Centre for Drug Design and Discovery in Belgium and Cancer Research Technology and MRC Technology in the U.K. are partnering on a translational research effort dubbed the Global Alliance of Leading Drug Discovery and Development Centres. The partners intend to use their alliances with biopharmaceutical companies to boost best practices and create standards and metrics to translate research into new therapies more quickly. Genetic Engineering & Biotechnology News (1/21) , GenomeWeb Daily News (free registration) (1/21) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  Advancing Health Care 
  From SNMMI 
  • SNMMI 2013 Annual Meeting online meeting planner now available!
    Visit the Meeting Planner and see what's happening at this year's Annual Meeting. With more than 100 CE sessions available, you'll quickly understand why thousands of professional attendees have called it the premier educational and networking event in nuclear medicine and molecular imaging. Register today. LinkedInFacebookTwitterEmail this Story
  • European Board of Nuclear Medicine Examination
    The European Board of Nuclear Medicine Examination, which leads to the European Fellowship, proves that the candidate’s knowledge and ability in nuclear medicine satisfy European standards. The European quality recognition is optional and does not interfere with the national requirements for specialization in nuclear medicine. The exam will be given twice in 2013. Get more information. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

Lend yourself to others, but give yourself to yourself."
--Michel de Montaigne,
French writer

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director:   Meryl Harold   (202) 407-7828
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.®  Legal Information